Albumin in Acute Ischemic Stroke Trial "ALIAS"

Terminated

Phase 3 Results N/A

Update History

16 Nov '12
A location was updated in Phoenix.
New
The overall status was removed for Mayo Clinic Hospital.
A location was updated in Tucson.
New
The overall status was removed for University of Arizona.
A location was updated in San Francisco.
New
The overall status was removed for University of California San Francisco and affiliated hospitals.
A location was updated in Stanford.
New
The overall status was removed for Stanford Medical Center.
A location was updated in Walnut Creek and Concord.
New
The overall status was removed for John Muir Medical Centers.
A location was updated in Miami.
New
The overall status was removed for University of Miami.
A location was updated in Ocala.
New
The overall status was removed for The Villages Research Group.
A location was updated in Atlanta.
New
The overall status was removed for Emory University and Grady Memorial Hospital.
A location was updated in Lexington.
New
The overall status was removed for University of Kentucky.
A location was updated in Detroit.
New
The overall status was removed for Henry Ford Hospital and affiliated hospitals.
A location was updated in Detroit.
New
The overall status was removed for Wayne State and affiliated hospitals.
A location was updated in Minneapolis.
New
The overall status was removed for University of Minnesota and affiliated hospitals.
A location was updated in Buffalo.
New
The overall status was removed for Millard Fillmore Gates Hospital.
A location was updated in New York City.
New
The overall status was removed for New York Presbyterian and affiliated hospitals.
A location was updated in Cincinnati.
New
The overall status was removed for University Hospital and affiliated hospitals.
A location was updated in Portland.
New
The overall status was removed for Oregon Health Science University and affiliated sites.
A location was updated in Abington.
New
The overall status was removed for University of Pennsylvania - Abington Hospital.
A location was updated in Houston.
New
The overall status was removed for University of Texas - Memorial Hermann.
A location was updated in Milwaukee.
New
The overall status was removed for Froedtert Memorial Hospital.
A location was updated in Calgary.
New
The overall status was removed for University of Calgary.
A location was updated in Edmonton.
New
The overall status was removed for University of Alberta.
A location was updated in Kamloops.
New
The overall status was removed for Royal Island Hospital.
A location was updated in Vancouver.
New
The overall status was removed for Vancouver General Hospital.
A location was updated in Halifax.
New
The overall status was removed for Dalhousie/Capital University.
A location was updated in Greenfield Park.
New
The overall status was removed for Hopital Charles LeMoyne, Centre de Recherche.
6 Oct '11
The eligibility criteria were updated.
New
Inclusion Criteria: - Acute ischemic stroke - NIH stroke scale score > 5 - Age >= 18 and <= 83 - ALB or placebo can be administered within 5 hours of symptom onset - ALB or placebo can be administered within 60 minutes of tPA administration in the thrombolysis group - Signed informed consent Exclusion Criteria: - Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6 months. An episode of congestive heart failure is any heart failure that required a change in medication, diet or hospitalization. - Known valvular heart disease with CHF in the last 6 months. - Severe aortic stenosis or mitral stenosis. - Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months. - Acute myocardial infarction in the last 6 months. - Signs or symptoms of acute myocardial infarction, including ECG findings, on admission. - Baseline elevated serum troponin level on admission (>0.1 mcg/L) - Suspicion of aortic dissection on admission. - Acute arrhythmia (including any tachycardia - or bradycardia) with hemodynamic instability. - Findings on physical examination of any of the following: (1) jugular venous distention (JVP > 4 cm above the sternal angle); (2) 3rd heart sound; (3) resting tachycardia (heart rate > 100/min) attributable to congestive heart failure; (4) abnormal hepatojugular reflux; (5) lower extremity pitting edema attributable to congestive heart failure; and/or (6) definite chest x-ray evidence of pulmonary edema. - Current acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy. - Historical mRS ≥2. Patients who live in a nursing home or who are not fully independent for activities of daily living immediately prior to the stroke are not eligible for the trial. - In-patient stroke. I.e., patients with a stroke occurring as a complication of hospitalization for another condition, or as a complication of a procedure. - Planned acute use of intra-arterial (IA) tPA or acute endovascular intervention (e.g., stenting, angioplasty, thrombus retrieval device use) must conform to the following criteria: (1) begin within 5 hours of symptom onset, and (2) finish within 7 hours of symptom-onset. - Fever, defined as core body temperature > 37.5oC (99.5oF). - Serum creatinine > 2.0 mg/dL or 180 µmol/L. - Profound dehydration. - Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT or MRI scan. - History of allergy to albumin. - History of latex rubber allergy. - Severe chronic anemia with Hgb < 7.5 g/dL - Pregnancy, breastfeeding or positive pregnancy test. (Women of childbearing age must have a negative pregnancy test prior to ALB administration.) - Concurrent participation in any other therapeutic clinical trial. - Evidence of any other major life-threatening or serious medical condition that would prevent completion of 3-month follow-up, impair the assessment of outcome, or in which ALB therapy would be contraindicated or might cause harm to the subject.
Old
Inclusion Criteria: - Acute ischemic stroke - NIH stroke scale score > 5 - Age >= 18 and <= 83 - ALB or placebo can be administered within 5 hours of symptom onset - ALB or placebo can be administered within 60 minutes of tPA administration in the thrombolysis group - Signed informed consent Exclusion Criteria: - Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6 months. An episode of congestive heart failure is any heart failure that required a change in medication, diet or hospitalization. - Known valvular heart disease with CHF in the last 6 months. - Severe aortic stenosis or mitral stenosis. - Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months. - Acute myocardial infarction in the last 6 months. - Signs or symptoms of acute myocardial infarction, including ECG findings, on admission. - Baseline elevated serum troponin level on admission (>0.1 mcg/L) - Suspicion of aortic dissection on admission. - Acute arrhythmia (including any tachycardia - or bradycardia) with hemodynamic instability. - Findings on physical examination of any of the following: (1) jugular venous distention (JVP > 4 cm above the sternal angle); (2) 3rd heart sound; (3) resting tachycardia (heart rate > 100/min) attributable to congestive heart failure; (4) abnormal hepatojugular reflux; (5) lower extremity pitting edema attributable to congestive heart failure; and/or (6) definite chest x-ray evidence of pulmonary edema. - Current acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy. - Historical mRS ?2. Patients who live in a nursing home or who are not fully independent for activities of daily living immediately prior to the stroke are not eligible for the trial. - In-patient stroke. I.e., patients with a stroke occurring as a complication of hospitalization for another condition, or as a complication of a procedure. - Planned acute use of intra-arterial (IA) tPA or acute endovascular intervention (e.g., stenting, angioplasty, thrombus retrieval device use) must conform to the following criteria: (1) begin within 5 hours of symptom onset, and (2) finish within 7 hours of symptom-onset. - Fever, defined as core body temperature > 37.5oC (99.5oF). - Serum creatinine > 2.0 mg/dL or 180 µmol/L. - Profound dehydration. - Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT or MRI scan. - History of allergy to albumin. - History of latex rubber allergy. - Severe chronic anemia with Hgb < 7.5 g/dL - Pregnancy, breastfeeding or positive pregnancy test. (Women of childbearing age must have a negative pregnancy test prior to ALB administration.) - Concurrent participation in any other therapeutic clinical trial. - Evidence of any other major life-threatening or serious medical condition that would prevent completion of 3-month follow-up, impair the assessment of outcome, or in which ALB therapy would be contraindicated or might cause harm to the subject.